Insight Molecular Diagnostics

Insight Molecular Diagnostics

Biotechnology
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

$81.5M

Market Cap • 11/6/2026

2009

(17 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

48,8

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

81,5M

EV

66,4M

EV/Revenue

39,7

EV/EBITDA

-1,4

EV/EBIT

-1,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-29,9%

Total Yield

-29,9%

Payout

0%

Retained Earnings

-416,3M

Profitability

Gross Margin

48,3%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

1146,5%

Capex/Revenue

234,8%

Capex/D&A

160,5%

Capex/OCF

-14,5%

SBC/OCF

—

% PPE

27,5%

% Goodwill

0%

ROE

488,7%

ROIC

—

Growth

CAGR Revenue 5Y

-16,9%

CAGR Op. Income 5Y

6,1%

CAGR Net Income 5Y

12,4%

CAGR EPS 5Y

-27%

CAGR OCF 5Y

-2,1%

Leverage

N.D./EBITDA

0,3

Debt/Equity

0%

Current Ratio

2

Quick Ratio

1,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium